Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Immacolata Pietraforte, Valeria Riccieri, Anna Mennella, Marius Cadar, Loredana Frasca, Katia Stefanantoni, Curdin Conrad, Raffaella Palazzo, Roberto Lande
Publikováno v:
Antibodies, Vol 10, Iss 12, p 12 (2021)
Antibodies
Volume 10
Issue 2
Antibodies, vol. 10, no. 2, pp. 12
Antibodies
Volume 10
Issue 2
Antibodies, vol. 10, no. 2, pp. 12
Chemokine (C-X-C motif) ligand 4 (CXCL4) is a biomarker of unfavorable prognosis in Systemic Sclerosis (SSc), a potentially severe autoimmune condition, characterized by vasculitis, fibrosis and interferon (IFN)-I-signature. We recently reported that
Publikováno v:
Antibodies, Vol 7, Iss 3, p 30 (2018)
Antibodies
Volume 7
Issue 3
Antibodies
Volume 7
Issue 3
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing
Publikováno v:
Antibodies, Vol 3, Iss 2, Pp 192-204 (2014)
Immune responses directed against clotting factor FVIII (FVIII) seriously complicate treatments for patients with hemophilia A. This response can manifest in congenital hemophilia A patients who generate inhibitor antibodies that bind and inactivate
Autor:
Satoshi Morimoto, Wanchai De-Eknamkul, Waraporn Putalun, Junichi Sakoda, Hiroyuki Tanaka, Ayako Takei, Thaweesak Juengwatanatrakul, Yukihiro Shoyama, Kaori Sasaki-Tabata, Madan Kumar Paudel, Oraphan Matangkasombut
Publikováno v:
Antibodies, Vol 1, Iss 3, Pp 273-283 (2012)
We prepared a monoclonal antibody (mAb 1C1) showing specificity for artemisinin (AM) and artesunate (AS), and we developed an indirect competitive enzyme-linked immunosorbent assay (icELISA) using this novel mAb. Moreover, we prepared a recombinant a
Publikováno v:
Antibodies, Vol 1, Iss 1, Pp 88-123 (2012)
Unmodified antibodies (abs) have been successful in the treatment of hematologic malignancies, but less so for the treatment of solid tumors. They trigger anti-tumor effects through their Fc-domains, and one way to improve their efficacy is to optimi